Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12

16 juin 2018

02:30
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Unfortunately, 40% of patients will relapse after or not respond to initial treatment resulting in poor outcomes especially if stem cell transplant is not an...

02:30
La macroglobulinémie de Waldenström (MW) est un type de cancer hématologique rare. Comme la MW est rare, il est difficile de mener des études cliniques de grande ampleur et de déterminer un traitement standard pour cette maladie. Le rituximab, un...

02:30
B acute lymphoblastic leukemia (B-ALL) is a fatal blood cell tumor that is usually treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HCT), and CD19-CAR-T cell therapy has been successful in treating refractory or...

02:30
Le lymphome diffus à grandes cellules B (LDGCB) est le type de lymphome non hodgkinien le plus répandu. Malheureusement, 40 % des patients rechutent ou ne réagissent pas au traitement initial, ce qui entraîne de mauvais pronostics, particulièrement...


15 juin 2018

13:20
Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas. They also speculate that...

08:00
Trovagene, Inc. , a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced completion of the first dose cohort of PCM-075, a highly-selective Polo-like...

08:00
More than 60 leading retinal disease clinical researchers from around the world gathered in Baltimore on June 11, 2018 to discuss findings from ProgStar, the Stargardt disease natural history study launched by the Foundation Fighting Blindness...

08:00
Blueprint Medicines Corporation , a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced updated data from its ongoing Phase 1 EXPLORER clinical trial of avapritinib, a potent...

08:00
MEI Pharma, Inc. a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announced that results from a Phase 1b study of ME-401 in patients with relapsed...

08:00
Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced preliminary data from Zella 201, an ongoing Phase 2 study evaluating the efficacy and safety...

07:04
Plus de 11 000 participants du monde entier sont attendus au 23[e] Congrès de l'Association européenne d'hématologie (AEH), qui se tiendra au Stockholmsmässan, à Stockholm, en Suède, du 14 au 17 juin 2018, au cours duquel les dernières données sur la...

07:00
Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WISh, presented today at the 23rd Congress...

07:00
ACell, Inc. today announced that promising data focused on its Gentrix Surgical Matrix family of devices for use in ventral hernia repair was presented at the recent Abdominal Wall Reconstruction conference in Washington, DC.  Gentrix® Surgical...

02:45
AbbVie , a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3 MURANO trial of venetoclax, a...

02:30
La chimio-immunothérapie (R-chimio) d'induction suivie d'un traitement de maintenance au rituximab est le traitement standard pour les lymphomes folliculaires (LF) symptomatiques non traités antérieurement. Le lénalidomide est un agent...

02:30
The anti-BCMA CAR T cell therapy bb2121 has demonstrated substantial activity in heavily pre-treated patients with multiple myeloma (MM). Updated results from 43 patients after five more months of follow-up show that bb2121 remains generally...

02:30
La thérapie bb2121 par lymphocytes T porteurs de CAR anti-BCMA a montré une activité substantielle chez les patients lourdement prétraités atteints d'un myélome multiple (MM). Les derniers résultats pour 43 patients après cinq mois supplémentaires de...

02:30
Le fer est un élément vital requis pour plusieurs fonctions biologiques, notamment l'apport en oxygène des tissus, qui s'effectue par l'entremise de l'hème, molécule contenant du fer au sein des globules rouges (GR). Le fer joue également un rôle clé...

02:30
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that is able to attack chronic lymphocytic leukemia (CLL) by binding and destroying malignant CLL cells. Rituximab is a non-glycoengineered type I anti-CD20 monoclonal antibody...

02:30
Purpose: To firstly study the anti-leukemic activity of the CLL1-CD33 compound CAR in vitro and in vivo and consequently offer opportunities to the treatment for refractory and relapsed AML patients.      (Logo:...

02:30
Chemoimmunotherapy (R-chemo) induction followed by rituximab maintenance is the standard of care in previously untreated, symptomatic follicular lymphoma (FL). Lenalidomide is an immunomodulatory agent with complementary mechanisms when combined with...

02:30
The anti-BCMA CAR T cell therapy bb2121 has demonstrated substantial activity in heavily pre-treated patients with multiple myeloma (MM). Updated results from 43 patients after five more months of follow-up show that bb2121 remains generally...

02:30
Six cycles of BEACOPP provide a better long-term disease control than ABVD in advanced Hodgkin lymphoma but is associated to more frequent hematological toxicity and a higher risk of myelodysplasia/acute leukemia and infertility. The AHL2011...

02:30
Iron is a vital element required for several biologic functions, first of all oxygen delivery to tissues, which occurs through the iron-containing molecule heme within red blood cells (RBC). Iron also plays key roles in inflammation and infections:...

02:30
L'obinutuzumab est un anticorps monoclonal anti-CD20 glycogénique de type II capable de combattre la leucémie lymphoïde chronique (LLC) en se liant aux cellules LLC malignes et en les détruisant. Le rituximab est un anticorps monoclonal anti-CD20 non...

02:30
Purpose: To firstly study the anti-leukemic activity of the CLL1-CD33 compound CAR in vitro and in vivo and consequently offer opportunities to the treatment for refractory and relapsed AML patients.      (Logo:...

02:30
Iron is a vital element required for several biologic functions, first of all oxygen delivery to tissues, which occurs through the iron-containing molecule heme within red blood cells (RBC). Iron also plays key roles in inflammation and infections:...

02:30
Objectif : Étudier tout d'abord l'activité antileucémique des cellules CAR composées (cCAR) CLL1-CD33 in vitro et in vivo, puis offrir par la suite des opportunités de traitement pour les patients atteints de leucémie aiguë myéloblastique (LAM)...

02:30
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that is able to attack chronic lymphocytic leukemia (CLL) by binding and destroying malignant CLL cells. Rituximab is a non-glycoengineered type I anti-CD20 monoclonal antibody...

02:30
L'administration de six cycles de BEACOPP permet une meilleure maîtrise à long terme de la maladie que l'ABVD dans le traitement du lymphome de Hodgkin avancé, mais elle est associée à une toxicité hématologique plus fréquente et à un risque plus...

02:30
Six cycles of BEACOPP provide a better long-term disease control than ABVD in advanced Hodgkin lymphoma but is associated to more frequent hematological toxicity and a higher risk of myelodysplasia/acute leukemia and infertility. The AHL2011...

02:30
Chemoimmunotherapy (R-chemo) induction followed by rituximab maintenance is the standard of care in previously untreated, symptomatic follicular lymphoma (FL). Lenalidomide is an immunomodulatory agent with complementary mechanisms when combined with...

01:00
UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatment and research, today presents findings from a patient survey entitled "Fears and Misconceptions of Women with Chronic Rheumatic Diseases Along Their Journey...


14 juin 2018

14:41
Leading researchers from neuroscience, molecular biology and bioengineering, discussed discoveries that drive the field of bioelectronic medicine forward at a recent three-day symposium. The Feinstein Institute for Medical Research, the Karolinska...

11:26
Taiho Oncology, Inc. and Servier today announced that clinical data for LONSURF® (trifluridine and tipiracil, TAS-102) are being presented at the ESMO 20th World Congress on Gastrointestinal Cancer 2018 (ESMO-GI) in Barcelona, Spain, June 20 to 23....

10:20
AIVITA Biomedical announced today the randomization of its first patient in the Company's Phase II clinical trial for newly diagnosed advanced ovarian cancer. The double-blind study will enroll approximately 99 patients who will receive AIVITA's...

10:00
Nektar Therapeutics today announced that new clinical and preclinical data for NKTR-181 were presented this week at the 80th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) in San Diego, California. NKTR-181 is a new...

09:45
Emosis débute la vente de HIT Confirm®, son premier test, via le réseau international de 5-Diagnostics   Emosis, société de dispositifs médicaux spécialisée dans les diagnostics cytomoléculaires des anomalies de l'hémostase, et 5-Diagnostics...

09:25
More than 11,000 participants from around the world are expected at the upcoming 23rd Congress of the European Hematology Association (EHA) at the Stockholmsmässan, Stockholm, Sweden on June 14-17, 2018, where the latest data on hematology research...

09:00
Demonstrating the power of student data scientists and researchers, Deloitte and the National Institutes of Health's (NIH) National Library of Medicine (NLM) celebrated two student-led research teams that made significant new virus and antibiotic...

09:00
14 abstracts to be presented, further characterizing the complementary profiles of Mavenclad (cladribine tablets)and Rebif (interferon beta-1a)   Merck, a leading science and technology company, will present data from its neurology and...

08:30
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the MERCURY PE study, which showed that people with low-risk pulmonary embolism (PE) treated with XARELTO® (rivaroxaban) and discharged from the emergency...

08:30
BioMarin Pharmaceutical Inc. announced today that the company dosed the first participant in a global Phase 2 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in infants and young children with achondroplasia, the most common...

08:00
SCYNEXIS, Inc. , a biotechnology company developing innovative therapies for difficult-to-treat and often life-threatening infections, today announced one poster presentation at ICHS, June 17-19, 2018, in Athens, Greece, one poster presentation at...

07:00
Apexigen, Inc., and Yale Cancer Center today announced a clinical trial collaboration to evaluate Apexigen's APX005M in combination with cabiralizumab and Opdivo in patients with advanced solid tumors. The Phase 1/2 clinical trial will evaluate the...

03:48
Emosis starts selling HIT Confirm®, Emosis' first test, through 5-Diagnostics' international network   Emosis, a medical device company specializing in cytomolecular diagnostics of hemostasis disorders, and 5-Diagnostics (5-D), a worldwide...

01:23
STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, congratulates its partner Ascletis for receiving approval from National Drug Administration of China (CNDA, former CFDA) of its Category 1 new drug, Ganovo® (also known as...


13 juin 2018

17:05
The Angiogenesis Foundation announced today it presented two pivotal food studies at the American Society for Nutrition's Annual Meeting Nutrition 2018 in Boston. The first study examined the antiangiogenic activity of broccoli florets and stems, and...

10:17
Actress Chéri Ballinger has invested in LifeStory Health, Inc. (LSH), a bio-science start-up developing novel diagnostics and potential therapeutic targets for early detection and treatment of female prevalent diseases. Ballinger, who survived a...

10:00
OWC Pharmaceutical Research Corp. , a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it has completed the pre-clinical development of its next generation,...

1 2 3 4 5 6 7 8 9 10 11 12